News
We provide the latest news from the world of economics and finance
(RTTNews) - Axsome Therapeutics (AXSM) announced the FDA has approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease. The FDA approval of AUVELITY is supported by a clinical program which included the Phase 3 ADVANCE-1 and ACCORD-2 studies.
AUVELITY is a first-in-class treatment for Alzheimer's disease agitation which targets the N-methyl D-aspartate and sigma-1 receptors. It was developed with FDA Breakthrough Therapy designation and evaluated by the FDA under Priority Review. AUVELITY is also FDA-approved for the treatment of major depressive disorder in adults.
At last close on NasdaqGM, Axsome shares were trading at $207.75, up 12.94%.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2026 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@j2t.com
